First time I am hearing India as a possible study setting. He said they are getting lots of requests and that CD16 will probably start there. Good to know that Cytodyn has already been investigated and contacted by relevant authorities there, their conversations giving Nader enough confidence to say that they will likely conduct trials in India. Hope FDA approves the protocol and this gets on quickly.
I've lost track of the trials. Long haulers, CD16 and two more critical trials CD17, 18 planned for Brazil. I don't think they have told us how these are different from CD 16, in terms of type of patients etc. Presumably the process is that they ask the FDA to conduct more trials in these hotspots, FDA agrees to accept the data from these places, and we conduct the trials there.
News 
Market Data 
Discover 
